Overview

Public BiotechPhase 4LSDketaminepsilocybin

Spun out from MAPS to develop MDMA-assisted therapy. After FDA declined approval in August 2024, underwent significant restructuring. Continuing to pursue MDMA therapy for PTSD.

Visit Website

San Jose, CA

2024
Founded
60
Employees
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline(5)

Unknown·N/A·LSD

Investigating Lysosomal Storage Diseases in Minority Groups

Lysosomal Storage Disorders
NCT02120235
Not Yet Recruiting·Phase 4·ketamine

An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium

Esketamine combined with dexmedetomidineDexmedetomidine
NCT07377981
Unknown·Phase 4·ketamine

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

EsketamineHepatocellular Carcinoma
NCT05416073
Unknown·Early Phase 1·psilocybin

A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients

Psilocybin-assisted therapy within a community of practice model (group administered)End of Life
NCT05958758
Completed·Phase 2·LSD

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

200 mcg LSDAnxiety
NCT00920387